<DOC>
	<DOCNO>NCT00992849</DOCNO>
	<brief_summary>The purpose current study ass efficacy safety inhibitory effect bevacizumab ( Avastin ) different route include topical subconjunctival application corneal neovascularization human eye .</brief_summary>
	<brief_title>Bevacizumab Treatment Corneal Neovascularization</brief_title>
	<detailed_description>The compassionate off-label use bevacizumab well potential risk , benefit , adverse effect medication discuss extensively patient . To minimize systemic absorption , silicone punctual plug place low eyelid . One group patient apply topical bevacizumab , 1.0 % ( 10mg/ml ) , 4 time day . The group patient receive subconjunctival injection bevacizumab ( 2.5mg/0.1ml ) . The patient examine 1day , 1week , 2weeks , 3weeks , 1month , monthly till corneal neovascularization go reduced degree . Best-corrected visual acuity , slip-lamp examination , tonometry , external photography , pachymetry , specular microscopy ( possible ) , systemic blood pressure complete visit .</detailed_description>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Corneal Neovascularization</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Significant unilateral bilateral corneal neovascularization extend limbus least 2mm . The underlying etiology cause corneal neovascularization include post penetrating keratoplasty ( PKP ) , ocular surface reconstruction , trauma , infectious noninfectious corneal ulcer . Corneal neovascularization induce lipid keratopathy , corneal edema , irregular corneal surface . The bestcorrected visual acuity less 20/25 . PostPSP ocular surface reconstruction corneal neovascularization associate lipid keratopathy , corneal edema , corneal irregularity . But neovascularization highly possible cause graft rejection . The corneal neovascularization refractory medical treatment . The patient receive PKP corneal surgery mort half year ago acute postoperation phase . The patient active endophthalmitis , glaucoma uncontrolled intraocular pressure , vitreoretinal disease . The patient sign inform consent regular follow treatment . The neovascularization clinical improvement three month first injection . The lipid keratopathy clinical improvement three month first injection . The patient suspect poor visual outcome already light sense negative Glaucoma patient uncontrolled intraocular pressure . Poor corneal epithelialization . Patient systemic disease suitable bevacizumab use . Pregnant patient .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Corneal neovascularization</keyword>
	<keyword>bevacizumab</keyword>
</DOC>